Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
Kintara Therapeutics (Nasdaq: KTRA) announced a multiyear research grant from the Luxembourg National Research Fund and Cancer Foundation Luxembourg to support Dr. Anna Golebiewska's research on VAL-083's mechanism of action in treating glioblastoma (GBM). The project aims to understand treatment resistance and improve patient stratification. VAL-083 is being advanced in the GBM AGILE study. This grant underscores Kintara's commitment to developing innovative cancer therapies, particularly for patients with limited treatment options.
Kintara Therapeutics (Nasdaq: KTRA) announced its CEO, Robert E. Hoffman, will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 a.m. ET on January 10 for 90 days. Based in San Diego, California, Kintara focuses on developing new cancer therapies, particularly VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer. These programs aim to address critical unmet medical needs and are progressing to late-stage testing.
Kintara Therapeutics, Inc. (Nasdaq: KTRA), based in San Diego, announced that CEO Robert E. Hoffman will present a corporate overview at the MedInvest Oncology Investor Conference, from December 7-10, 2021. Hoffman's presentation is scheduled for December 9 at 2:50 p.m. EST, and he will be available for one-on-one meetings during the event. Kintara is focused on developing innovative cancer therapies, including VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer, both of which are in late-stage clinical development.
Kintara Therapeutics (Nasdaq: KTRA) announced the activation of its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) Phase 2/3 clinical trial for glioblastoma multiforme at Sunnybrook Health Sciences Centre in Toronto. As of November 24, 2021, Kintara is actively recruiting at 30 U.S. sites, with plans to enroll 150-200 patients across over 40 sites. The GBM AGILE trial aims to identify effective therapies for GBM and may expedite FDA submissions. The company is also advancing other late-stage therapies for unmet medical needs.
Kintara Therapeutics (Nasdaq: KTRA) has presented promising results from two Phase 2 studies of VAL-083 for treating glioblastoma multiforme (GBM) at the Society for Neuro-Oncology Annual Meeting. In one study, newly diagnosed patients showed a median overall survival (mOS) of 19.1 months and a progression-free survival (PFS) of 8.7 months, outperforming historical controls. The second study reported an mOS of 8.0 months in recurrent GBM patients. Both studies reported myelosuppression as the most common adverse effect. Kintara is advancing VAL-083 for GBM and REM-001 for CMBC.
Kintara (Nasdaq: KTRA) reported its fiscal first-quarter results for the period ending September 30, 2021. The company had cash and cash equivalents of approximately $19.3 million and a net loss of about $6.0 million, significantly reduced from $19.5 million in the same quarter last year. Kintara highlighted progress in its clinical trials for VAL-083 in glioblastoma and REM-001 for breast cancer, with significant data indicating progression-free survival rates. Additionally, it raised $15.0 million from institutional investors for ongoing studies.
Kintara Therapeutics (Nasdaq: KTRA) will present at the Q4 Investor Summit Conference on November 17, 2021, at 1:15 p.m. ET. CEO Robert E. Hoffman will provide a corporate overview and is available for one-on-one meetings throughout the event. The company is focused on developing novel therapies for rare cancers, with two Phase 3-ready treatments: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Kintara's VAL-083 has shown clinical promise across multiple cancers, while REM-001 displays an 80% efficacy in prior studies.
Kintara (Nasdaq: KTRA) announced a leadership change on November 8, 2021, with Robert E. Hoffman succeeding Saiid Zarrabian as President and CEO. Hoffman will retain his role as Chairman, while Zarrabian transitions to leading strategic partnerships. This change is positioned as a pivotal moment as Kintara prepares for the final stages of clinical development for VAL-083, crucial for treating glioblastoma. The company aims to expedite regulatory submission timelines by participating in the FDA-approved GBM AGILE study, with sufficient funding secured through stage 1 of the trial.
Kintara Therapeutics (Nasdaq: KTRA) will be presenting at the 14th Annual LD Micro Main Event Conference held in Los Angeles from October 12-14, 2021. CEO Saiid Zarrabian is scheduled to deliver a corporate overview on October 12 at 2:00 p.m. PT. Kintara focuses on developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. The presentation will highlight Kintara’s advancements in clinical trials and therapeutic development.
Kintara (Nasdaq: KTRA) reported its fiscal year 2021 financial results, highlighting a net loss of approximately $38.3 million, or $1.60 per share, up from a loss of $9.1 million in 2020. The company successfully raised $15 million through a registered direct offering and advanced patient enrollment in its GBM AGILE study with 26 clinical trial sites activated. Notable safety and efficacy results for its therapy VAL-083 were reported from Phase 2 studies, demonstrating promising progression-free survival.